Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7090333 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL10643050 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL3681429 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL14917423 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL3680436 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL187893 | 1.00 | — | — | |
| SCHEMBL16353877 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL190431 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL2701918 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL105641 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023019181-A1 | SARS-COV-2 LIPID NANOPARTICLE VACCINE FORMULATIONS | MODERNATX, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| US-10155945-B2 | Method of producing lipid nanoparticles for drug delivery | NITTO DENKO CORPORATION (JP) | 2018-12-18 | — | — | US | disclosed |
| US-9579338-B2 | Method of producing lipid nanoparticles for drug delivery | NITTO DENKO CORPORATION (JP) | 2017-02-28 | — | — | US | disclosed |
| US-8956572-B2 | Single use system for sterilely producing lipid-nucleic acid particles | NITTO DENKO CORPORATION (JP) | 2015-02-17 | — | — | US | disclosed |
| US-20130164400-A1 | SINGLE USE SYSTEM FOR STERILELY PRODUCING LIPID-NUCLEIC ACID PARTICLES | NITTO DENKO CORPORATION (JP) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130164400-A1 | SINGLE USE SYSTEM FOR STERILELY PRODUCING LIPID-NUCLEIC ACID PARTICLES | RNGTT, SPOUT1, NASP | MEN1 1750/4885KMT2A 2971/4885TSHR 4621/4885 |
| US-10155945-B2 | Method of producing lipid nanoparticles for drug delivery | PHOSPHO1, LIPA, LIPC | MEN1 1326/4885KMT2A 1899/4885TSHR 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.